|
BioScreening - organic compounds for screening
News: CollaborationsCRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform - Munich and Freiburg, Germany, May 7, 2008 / b3c newswire / – CRELUX and ProQinase announced today that they have entered into a joint agreement to supply customers with crystal-grade protein kinases and readily available kinase complex structures.
Under the agreement, CRELUX and ProQinase will establish and continuously expand an off-the-shelf crystal-grade protein kinase portfolio, optimized [...]
Invitrogen Scientists Link microRNA Sequences to Cancer Using RNA Samples from BioServe - Carlsbad, Calif., and Beltsville, Md., May 7, 2008 – In research demonstrating that RNA previously thought to have no biological relevance may be of use for therapeutic and diagnostic targets, Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, and BioServe, the leading provider of clinically annotated tissue samples [...]
CLC bio to collaborate with Microsoft on integrating life science technology - Boston, USA — April 29, 2008 — Today at the Bio-IT World Conference & Expo in Boston, USA, CLC bio announced collaboration with Microsoft Corp. on integrating CLC bio’s extensive bioinformatics solutions with Microsoft’s software platform, for the benefit of companies, corporations, and institutions in the biotech, pharmaceutical, and life science sectors. CLC bio has [...]
Ono Enters into a New Fragment-Based Drug Discovery Agreement with Evotec - Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT) announced today that the Company and Ono Pharmaceutical Co., Ltd. (Osaka, Japan) signed a new drug discovery agreement targeting a protease chosen by Ono.
The collaboration applies Evotec’s proprietary fragment-based drug discovery platform, EVOlutionTM to identify novel, small molecular weight compounds active against a [...]
Spermatech Selects Evotec as Partner for High-Throughput Screening and Lead Discovery - Hamburg, Germany | Oxford, UK | Oslo, Norway - Evotec AG (Frankfurt Stock Exchange: EVT) announced today that Spermatech A/S has chosen them as a partner to identify small molecule therapeutics for their pharmaceutical discovery project.
Through the study of the physiology of sperm motility, more specifically of “rapid swimmers” that cause fertilisation, Spermatech have identified [...]
Spermatech Selects Evotec as Partner for High-Throughput Screening and Lead Discovery - HAMBURG, Germany and OXFORD, England and OSLO, March 12, 2008 /PRNewswire-FirstCall/ — Evotec AG announced today that Spermatech A/S has chosen them as a partner to identify small molecule therapeutics for their pharmaceutical discovery project.
Through the study of the physiology of sperm motility, more specifically of “rapid swimmers” that cause fertilisation, Spermatech have identified biological [...]
Evotec Expands Collaboration with InterMune - Hamburg, Germany | Oxford, UK- Evotec AG (Frankfurt Stock Exchange: EVT) today announced that InterMune, Inc., has signed a second drug discovery contract with Evotec.
Evotec will support InterMune’s research efforts using their medicinal chemistry know-how. In addition, they will utilize their expertise and technologies in computational chemistry, protein production, X-Ray crystallography and ADMET to further [...]
Burnham Institute Selects Labcyte Acoustic Liquid Handling Technology - Sunnyvale, CA November 15, 2007 - Labcyte Inc. will supply Burnham Institute for Medical Research (Burnham) with more than $2.3 million worth of Echo® liquid handlers for use in screening large biological libraries. The systems will be installed at both the Institute’s LaJolla, (CA) and Lake Nona, Orlando (FL) campuses. These instruments will be part [...]
Graffinity Announces Multitarget Drug Discovery Research Collaboration With Pfizer - Heidelberg, Germany, November 29, 2007 /b3c newswire/ — Graffinity Pharmaceuticals GmbH announced today that it has entered into its second drug discovery collaboration with Pfizer, Inc. Through the collaboration, Graffinity will provide Pfizer with access to its proprietary, fragment-based screening technology for use in screening Pfizer drug targets. The agreement [...]
Magellan BioScience Group, Inc. and the University of Medicine and Dentistry of New Jersey enter into anti-Leukemia Drug Discovery Collaboration - Tampa, FL – Magellan BioScience Group, Inc. (Magellan), a pioneer in innovative drug discovery and development from marine microbial sources, and the University of Medicine and Dentistry of New Jersey (UMDNJ) announced today that they have entered into an anti-leukemia drug discovery collaboration. Magellan will team with UMDNJ scientist Dr. Scott Kachlany.
This collaboration will bring [...]
Bio-IT Briefs - November 01, 2007 | Ambit Biosciences announced a second expansion of its collaboration with Bristol-Myers Squibb (BMS) for the discovery and development of novel kinase inhibitors. As part of this expansion, Ambit will screen BMS’s kinase-focused library using Ambit’s proprietary KinomeScan technology. KinomeScan is a high-throughput method for screening small molecule libraries against a large [...]
Bucks County’s Institute for Hepatitis and Virus Research and BioLeap Collaborate on New Discoveries - New Hope, PA — (SBWIRE) — 10/10/2007 — Bucks County’s Institute for Hepatitis and Virus Research (IHVR) and BioLeap have entered into a collaboration to develop new therapeutic compounds for the treatment of Hepatitis C. Up to 50% of patients treated with current standard therapies do not respond adequately and often suffer serious side effects [...]
InnoVet Selects EBD Group to Power its Conference Partnering - Carlsbad, CA , October 09, 2007 – EBD Group, the leading partnering firm for the global biotechnology industry, today announced that it has been selected to run the partnering facility for InnoVet 2007, the premier international veterinary business conference and partnering event held this year in Charlottetown, Prince Edward Island, Canada, October 14-16, 2007. InnoVet [...]
BIOSERVE and DNAPRINT(R) GENOMICS FORM STRATEGIC ALLIANCE TO PROVIDE CLINICAL PATIENT SAMPLES TAGGED WITH GENETIC ANCESTRY DATA - BioServe’s fully annotated clinical samples across many diseases to be tagged with ancestry information using DNAPrint’s genetic ancestry tests
BELTSVILLE, MD., Oct. 9, 2007 – BioServe today announced the formation of strategic alliance with DNAPrint® Genomics, Inc. (OTCBB: DNAG) to provide biomedical researchers with clinical DNA samples that for the first time will include genetic ancestry [...]
BIO-Europe 2007 Plays Host to the Largest Number of International Delegations in its 13 Year History - Munich, Germany, and Washington D.C., Sept. 17, 2007 – Globalization is the nature of the life sciences industry. EBD Group and the Biotechnology Industry Organization (BIO) announce that BIO-Europe 2007 will include an even greater number of international delegations of biotech companies seeking strategic biotech partnerships than previous years.
[...]
Cisbio has entered into a partnership agreement with Lumiphore to gain access to new fluorescence reporter molecules for use in its high throughput (HT) screening assays. - The agreement grants Cisbio exclusive access to the Lumi4 compounds for fluorescence applications in drug discovery, with Lumiphore free to develop partnerships to develop the technology in other areas.
Cisbio has played an important part in the development of HT drug screening technologies and has enabled researchers to conduct binding assays based on its homogenous time-resolved [...]
Tikvah Therapeutics, Inc. And Chakra Biotech Pte. Ltd. Establish Collaboration To Accelerate The Development Of Novel Antipsychotic Compounds - SINGAPORE, Norway, Sept 6, 2007 - (Hugin via ACN Newswire) - ATLANTA and SINGAPORE, Sept. 6, 2007 (PRIME NEWSWIRE) — Tikvah Therapeutics, Inc., a biopharmaceutical company focused on new treatment options to better manage central nervous system diseases, and Chakra Biotech Pte. Ltd., a drug discovery and development company focusing on central nervous system disorders, [...]
BioServe and Phenomenome Discoveries Develop Novel Diagnostic Test for Colorectal Cancer - Laurel, MD and Saskatoon, SK, Canada, August 6, 2007 – BioServe and Phenomenome Discoveries Inc. (“PDI”) today announced that they have developed a novel serum-based diagnostic test for the identification of colorectal cancer (CRC), and pre-cancerous states conducive to the development of CRC. Colorectal cancer comprises a tenth of the global [...]
Hydra Biosciences and Pfizer Global Research & Development Sign Collaboration Agreement - CAMBRIDGE, Mass.–(BUSINESS WIRE)–Hydra Biosciences announced today that it has signed a collaboration agreement with Pfizer Global Research & Development. The collaboration will be focused on TRPV3 antagonist product candidates for pain.
The Transient Receptor Potential (TRP) channel family comprises a novel [...]
Oswaldo Cruz Foundation and Genzyme Corporation Form Collaboration To Advance New Drugs for Neglected Diseases - BRASILIA, Brazil and CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ — The Oswaldo Cruz Foundation (Fiocruz) and Genzyme Corp. today announced that they have formed a research collaboration to advance new treatments for certain neglected diseases. The partners will focus initially on Chagas disease, a life-threatening infectious disease affecting millions of people in Latin America.
Fiocruz, a premier [...]
|
|
